• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Spero Therapeutics Inc.

    8/12/25 5:12:49 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRO alert in real time by email
    S-8 1 d24105ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 12, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SPERO THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-4590683

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    675 Massachusetts Avenue, 14th Floor

    Cambridge, Massachusetts

      02139
    (Address of Principal Executive Offices)   (Zip Code)

    SPERO THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN, AS AMENDED

    (Full title of the plan)

    Esther Rajavelu, President, Chief Executive Officer, Chief Financial Officer and Treasurer

    Spero Therapeutics, Inc.

    675 Massachusetts Avenue, 14th Floor

    Cambridge, Massachusetts 02139

    (Name and address of agent of service)

    (857) 242-1600

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This registration statement registers an aggregate of 3,000,000 additional shares of common stock of Spero Therapeutics, Inc. (the “Registrant”) reserved under the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (the “2017 Plan”), representing an increase of 3,000,000 shares reserved under the 2017 Plan effective June 12, 2025. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 relating to the 2017 Plan has previously been filed and is effective. This registration statement incorporates by reference the contents of (i) the registration statement on Form S-8 (File No. 333-222060), filed with the Securities and Exchange Commission on December 14, 2017 by the Registrant, (ii) the registration statement on Form S-8 (File No.  333-230281), filed with the Securities and Exchange Commission on March 14, 2019 by the Registrant, (iii) the registration statement on Form S-8 (File No.  333-237283), filed with the Securities and Exchange Commission on March 19, 2020 by the Registrant, (iv) the registration statement on Form S-8 (File No.  333-254173), filed with the Securities and Exchange Commission on March 11, 2021 by the Registrant, (v) the registration statement on Form S-8 (File No.  333-259662), filed with the Securities and Exchange Commission on September 20, 2021 by the Registrant, (vi) the registration statement on Form S-8 (File No.  333-268344), filed with the Securities and Exchange Commission on November 14, 2022 by the Registrant, (vii) the registration statement on Form S-8 (File No.  333-275514), filed with the Securities and Exchange Commission on November 13, 2023 by the Registrant, and (viii) the registration statement on Form S-8 (File No.  333-281245), filed with the Securities and Exchange Commission on August 5, 2024 by the Registrant, in each case, except for Item 8, Exhibits.


    Item 8. Exhibits.

     

    Exhibit
    Number
      

    Exhibit Description

       Filed
    Herewith
         Incorporated by
    Reference
    herein from
    Form or
    Schedule
        Filing Date      SEC File/
    Reg. Number
     
     4.1    Form of Common Stock Certificate of Registrant.        

    Form S-1

    (Exhibit 4.1

     

    ) 

        10/6/2017        333-220858  
     4.2    Amended and Restated Certificate of Incorporation of the Registrant.        

    Form 8-K

    (Exhibit 3.1

     

    ) 

        11/6/2017        001-38266  
     4.3    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.        

    Form 8-K

    (Exhibit 3.1

     

    ) 

        8/18/2021        001-38266  
     4.4    Amended and Restated Bylaws of the Registrant.        

    Form 10-Q

    (Exhibit 3.1

     

    ) 

        11/13/2023        001-38266  
     5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.      X          
    23.1    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.      X          
    23.2    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in opinion of counsel filed as Exhibit 5.1).      X          
    24.1    Power of Attorney (set forth on the signature page of this registration statement).      X          
    99.1    2017 Stock Incentive Plan, as amended.        

    Form 10-Q

    (Exhibit 10.1

     

    ) 

        8/12/2025        001-38266  
    99.2    Form of Stock Option Agreement under the 2017 Stock Incentive Plan, as amended.        

    Form S-8

    (Exhibit 4.6

     

    ) 

        9/20/2021        333-259662  
    99.3    Form of Restricted Stock Unit Agreement under the 2017 Stock Incentive Plan, as amended.        

    Form 8-K

    (Exhibit 10.1

     

    ) 

        8/30/2021        001-38266  
    107    Filing Fee Table.      X          


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on August 12, 2025.

     

    SPERO THERAPEUTICS, INC.
    By:   /s/ Esther Rajavelu
      Esther Rajavelu
      President, Chief Executive Officer, Chief Financial Officer and Treasurer

    POWER OF ATTORNEY AND SIGNATURES

    Each person whose signature appears below constitutes and appoints Esther Rajavelu and Timothy Keutzer, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Spero Therapeutics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature    Title   Date

    /s/ Esther Rajavelu

    Esther Rajavelu

      

    President, Chief Executive Officer, Chief Financial Officer and Treasurer

    (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

      August 12, 2025

    /s/ Frank E. Thomas

    Frank E. Thomas

       Chairman   August 12, 2025

    /s/ Milind Deshpande, Ph.D.

    Milind Deshpande, Ph.D.

       Director   August 12, 2025

    /s/ Scott Jackson

    Scott Jackson

       Director   August 12, 2025

    /s/ Ankit Mahadevia, M.D.

    Ankit Mahadevia, M.D.

       Director   August 12, 2025

    /s/ John C. Pottage, M.D.

    John C. Pottage, M.D.

       Director   August 12, 2025

    /s/ Cynthia Smith

    Cynthia Smith

       Director   August 12, 2025

    /s/ Kathleen Tregoning

    Kathleen Tregoning

       Director   August 12, 2025

    /s/ Patrick Vink, M.D.

    Patrick Vink, M.D.

       Director   August 12, 2025
    Get the next $SPRO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRO

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SPRO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Spero Therapeutics Inc.

    SCHEDULE 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    8/14/25 9:48:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Spero Therapeutics Inc.

    S-8 - Spero Therapeutics, Inc. (0001701108) (Filer)

    8/12/25 5:12:49 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Spero Therapeutics Inc.

    10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)

    8/12/25 4:31:07 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mahadevia Ankit was granted 20,000 shares, increasing direct ownership by 3% to 709,866 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:32:05 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deshpande Milind was granted 20,000 shares, increasing direct ownership by 28% to 91,454 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:30:52 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jackson Scott Thomas was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:29:35 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Spero Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

    12/20/24 7:51:16 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

    9/23/22 7:52:34 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

    10/1/21 6:10:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Financials

    Live finance-specific insights

    View All

    Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

    PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company foc

    8/12/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

    CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be

    8/5/25 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

    CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

    5/5/25 8:00:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

    PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company foc

    8/12/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

    CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be

    8/5/25 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

    If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation

    5/28/25 7:00:00 AM ET
    $GSK
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    11/14/24 5:37:55 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Spero Therapeutics Inc.

    SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/24 4:25:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/23 11:47:54 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Leadership Updates

    Live Leadership Updates

    View All

    Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

    CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

    4/28/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

    CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

    11/1/23 8:05:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

    9/12/23 8:00:00 AM ET
    $PTCT
    $SPRO
    $TCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)